PT  - JOURNAL ARTICLE
AU  - Qian Wang
AU  - Lei Yang
AU  - Yang Ge
AU  - Dong Yan
AU  - Guosheng Feng
AU  - Guangyu An
AU  - Yingmin Ma
TI  - Changes in lymphocyte subgroups of non-small cell lung cancer patients during chemotherapy
AID  - 10.1183/13993003.congress-2015.PA4271
DP  - 2015 Sep 01
TA  - European Respiratory Journal
PG  - PA4271
VI  - 46
IP  - suppl 59
4099  - http://erj.ersjournals.com/content/46/suppl_59/PA4271.short
4100  - http://erj.ersjournals.com/content/46/suppl_59/PA4271.full
SO  - Eur Respir J2015 Sep 01; 46
AB  - Objective: Many NSCLC patients require chemotherapy,which is extremely damaging to the immune system.This study was undertaken to investigate changes in lymphocyte subgroups in patients before and during chemotherapy.Methods: NSCLC patients (32) who were undergoing their initial chemotherapy were enrolled. Lymphocyte subgroups (CD3+, CD4+, CD8+, CD4+/CD8+, CD3-CD16+CD56+, CD3+CD16+CD56+, CD19+, CD8+CD28-, CD8+CD28+ and DC1/DC2) were examined via flow cytometry in 9 time points.Results: Most of the subgroups were increased slightly before the second cycle of chemotherapy and began to decline during the second cycle,and during the third and fourth cycles,their lymphocyte subgroups were significantly decreased compared with pre-chemotherapy (p<0.05). CD4+,CD8+CD28+ and DC1/DC2 were associated with tumor progression In the two efficacy assessments(p<0.05). Conclusions: It is vital for clinicians to use ancillary and immuomodulatory drugs or adjust medication programs and doses to restore or enhance the body's immune functions. CD4+,CD8+CD28+ and DC1/DC2 are proposed to serve as useful new indicators for evaluating chemotherapeutic efficacy in NSCLC patients.